

Carmine Giorgio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/676830/publications.pdf>

Version: 2024-02-01

30
papers

719
citations

430874

18
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

984
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Eph/ephrin system in cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2017, 142, 152-162.	5.5	80
2	Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. <i>PLoS ONE</i> , 2011, 6, e18128.	2.5	66
3	Amino Acid Conjugates of Lithocholic Acid As Antagonists of the EphA2 Receptor. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2936-2947.	6.4	50
4	Ocotea quixos Lam. essential oil: In vitro and in vivo investigation on its anti-inflammatory properties. <i>FÄ-toterapÄ-Äç</i> , 2010, 81, 289-295.	2.2	41
5	Therapeutic perspectives of EphÄ“ephrin system modulation. <i>Drug Discovery Today</i> , 2014, 19, 661-669.	6.4	38
6	Î”5-Cholenoyl-amino acids as selective and orally available antagonists of the EphÄ“ephrin system. <i>European Journal of Medicinal Chemistry</i> , 2015, 103, 312-324.	5.5	38
7	Studies on the antiplatelet and antithrombotic profile of anti-inflammatory coumarin derivatives. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 30, 925-933.	5.2	33
8	Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New ProteinÄ“Protein Interaction Inhibitors Targeting the EphA2 Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 787-796.	6.4	32
9	StructureÄ“Activity Relationships and Mechanism of Action of EphÄ“ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor. <i>ChemMedChem</i> , 2012, 7, 1071-1083.	3.2	31
10	The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. <i>Molecular Nutrition and Food Research</i> , 2015, 59, 2155-2167.	3.3	31
11	UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. <i>Oncotarget</i> , 2018, 9, 24347-24363.	1.8	28
12	Target Hopping as a Useful Tool for the Identification of Novel EphA2 ProteinÄ“Protein Antagonists. <i>ChemMedChem</i> , 2014, 9, 67-72.	3.2	27
13	Perturbation of the EphA2Ä“EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites. <i>Journal of Agricultural and Food Chemistry</i> , 2012, 60, 8877-8884.	5.2	25
14	1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10H-pyrimido[1,2-a][1,8]naphthyridine-6-carboxamide derivative. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 394-405.	5.5	24
15	Targeting the Eph/Ephrin System as Anti-Inflammatory Strategy in IBD. <i>Frontiers in Pharmacology</i> , 2019, 10, 691.	3.5	22
16	1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3379-3387.	3.0	21
17	Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. <i>Biochemical Pharmacology</i> , 2018, 147, 21-29.	4.4	20
18	Polyphenol rich botanicals used as food supplements interfere with EphA2Ä“ephrinA1 system. <i>Pharmacological Research</i> , 2011, 64, 464-470.	7.1	19

#	ARTICLE	IF	CITATIONS
19	Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiplothetic activities evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1125-1129.	2.2	17
20	Exploiting Free Energy Minima to Design Novel EphA2 Protein Antagonists: From Simulation to Experiment and Return. <i>Chemistry - A European Journal</i> , 2016, 22, 8048-8052.	3.3	15
21	Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. <i>Molecules</i> , 2013, 18, 13043-13060.	3.8	13
22	Combining Ligand- and Structure-Based Approaches for the Discovery of New Inhibitors of the EphA2-ephrin-A1 Interaction. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 2621-2626.	5.4	13
23	Ephrin or not? Six tough questions on Eph targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 403-415.	3.4	10
24	Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. <i>Biochemical Pharmacology</i> , 2016, 99, 18-30.	4.4	6
25	Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 180, 113067.	2.8	5
26	Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3- β -carbamoyloxy derivative with antiangiogenic properties. <i>European Journal of Medicinal Chemistry</i> , 2020, 189, 112083.	5.5	5
27	Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids. <i>Pharmaceuticals</i> , 2022, 15, 137.	3.8	5
28	UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling. <i>Pharmaceuticals</i> , 2021, 14, 502.	3.8	2
29	Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph-Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice. <i>Pharmaceuticals</i> , 2022, 15, 41.	3.8	2
30	Evaluation of the Anti-Tumor Activity of Small Molecules Targeting Eph/Ephrins in APC min/J Mice. <i>Pharmaceuticals</i> , 2020, 13, 69.	3.8	0